SGLT-2 inhibitors

Module 1: Introducing SGLT-2 inhibitors: history and mode of action

Please log in to access the chapters in this module.
CME Credits: 0.5
Module duration: 0.5 hours
Launch date: Winter 2023 (version 1)
Updated: -
Expiry date: March 2027
Audience: Diabetes and Metabolism Specialists (Basic), Endocrinologists (Basic)

Hello, I'm Professor David Matthews and I'm Emeritus Professor of Diabetes at the University of Oxford. This module is about SGLT-2 inhibitors, and by the end of this short film you should be aware of how SGLT-2 inhibitors work.

This module introduces the sodium-glucose co-transporter-2 (SGLT-2) inhibitor drug class and a series of animations demonstrate how SGLT-2 inhibitors work and the consequences of SGLT-2 blockade.

Kalra S. Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology. Diabetes Ther (2014) 5:355–366.
http://pubmed.ncbi.nlm.nih.gov/25424969/

Assessment will rely in part on learners having read the following article referenced in this module.

Learning Outcomes

By the end of this module, you will be able to:

Explain the physiology of normal renal glucose absorption and the alterations occurring in people with diabetes

Explain the mode of action of SGLT-2 inhibitors

Apply your knowledge of SGLT-2 inhibitors in a clinical setting, including the treatment of people with diabetes


This module includes self-marked assessments, such as knowledge checks and/or case studies, as well as a marked final assessment, which you can attempt up to five times. To complete the module, you must review all chapters, pass the final assessment (80% pass mark), and fill in our feedback form.


Contributors

Professor (Emeritus)
David Matthews
Author, Assessment Setter
Professor
Francesco Giorgino
Expert Reviewer
Assessment Setter
Assessment Setter